Company news
Alligator Bioscience Ab (OMXSTO:ATORX) news
Every Alligator Bioscience Ab press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Bulletin from the Extraordinary General Meeting in Alligator Bioscience AB
August 26, 2026
Invitation to Alligator Bioscience's Earnings Call on 26 August 2026
August 20, 2026
Alligator Bioscience AB reports financial results for the period 1 January – 31 March 2026 and provides a business update
May 5, 2026
Invitation to Alligator Bioscience's Earnings Call on 5 May 2026
April 28, 2026
Alligator Bioscience Comments on Henlius Presentation of HLX49 Preclinical Data at AACR 2026
April 23, 2026
New Data from Investigator‑Initiated Study Evaluating Alligator Bioscience’s Mitazalimab to Be Presented at AACR Annual Meeting 2026
April 20, 2026
Alligator Bioscience Provides an Update on Mitazalimab
April 10, 2026
Notice of Annual General Meeting in Alligator Bioscience AB
March 30, 2026
The Nomination Committee's Proposals Regarding the Board of Directors for the Annual General Meeting in Alligator Bioscience AB (publ)
March 27, 2026
Alligator Bioscience Publishes Annual Report for 2025
March 26, 2026
Alligator Bioscience AB announces outcome of exercise of warrants series TO 14
March 20, 2026
Management intends to subscribe pro rata in Alligator Bioscience’s warrant program TO 14
March 16, 2026
Alligator Bioscience Strengthens Intellectual Property Protection for Bispecific Antibody Platform
March 10, 2026
Alligator Bioscience Comments on Henlius Dosing First Patient in Phase 2/3 Breast Cancer Study of HLX22
March 2, 2026
Exercise Price Determined for the Exercise of Warrants Series TO 14 in Alligator Bioscience AB
February 27, 2026
Alligator Bioscience AB Reports Full Year Financial Results for 2025 and for Q4 2025 and Provides a Business Update
February 12, 2026
Invitation to Alligator Bioscience's Earnings Call on 12 February 2026
February 5, 2026
Change in Number of Shares and Votes in Alligator Bioscience AB
January 30, 2026
Alligator Bioscience to Present New OPTIMIZE-1 Data on Mitazalimab at ASCO Gastrointestinal Cancers Symposium 2026
January 9, 2026
Alligator Bioscience Announces Preliminary Outcome in Rights Issue
December 19, 2025
Alligator Bioscience Comments on Henlius Receiving Regulatory Approval in China to Initiate Phase 2/3 Trials of HLX22 in HER2-Positive Br...
December 9, 2025
Alligator Publishes Supplement Prospectus
December 3, 2025
Alligator Bioscience Publishes Financial Calendar for 2026
December 3, 2025
Alligator Bioscience Enters into Additional Subscription Undertakings and Top Guarantee Commitments for the Upcoming Rights Issue
December 1, 2025
Alligator Bioscience Announces Publication of REACtiVe-2 Phase 1 trial data in Nature Communications
December 1, 2025
Bulletin from The Extraordinary General Meeting in Alligator Bioscience AB
November 25, 2025
Alligator Bioscience Presents New Data on Mitazalimab and ATOR-4066 at SITC 40th Anniversary Annual Meeting
November 5, 2025
Nomination Committee Appointed in Respect of AGM 2026 in Alligator Bioscience AB
November 3, 2025
Alligator Bioscience AB Reports Financial Results for Q3 2025 and Provides a Business Update
October 23, 2025
Notice of Extraordinary General Meeting in Alligator Bioscience AB
October 22, 2025
Alligator Bioscience Carries Out a Rights Issue of Units of Approximately SEK 120 Million and Raises Bridge Loans
October 22, 2025
Alligator Bioscience Granted US Patent Covering ATOR-4066 Bispecific Antibody
October 21, 2025
Invitation to Alligator Bioscience's Earnings Call on 23 October 2025
October 16, 2025
REACtiVe-2 Phase 1 Data Featuring Mitazalimab Demonstrate Immune Activation in Metastatic Pancreatic Cancer - To be Presented at ESMO 2025
October 13, 2025
Alligator Announces Publication of OPTIMIZE-1 Biomarker Analysis in Cell Reports Medicine Supporting mitazalimab and mFOLFIRINOX in Metas...
October 8, 2025
Alligator Bioscience Announces Acceptance of Two Abstracts at SITC 40th Anniversary Annual Meeting
October 6, 2025
Alligator Announces Final 30-Month OPTIMIZE-1 Results Highlighting the Potential of Mitazalimab in Metastatic Pancreatic Cancer
September 22, 2025
Alligator Bioscience AB Announces Final Outcome of Exercise of Warrants Series TO 13
September 17, 2025
Alligator Bioscience AB Announces Preliminary Outcome of Exercise of Warrants Series TO 13
September 16, 2025
Alligator to Present New Preclinical Results on ATOR-4066 at CICON25
September 12, 2025
Alligator Announces Publication in Cancer Immunology Research of Preclinical Data on ATOR-4066, a Tumor-Directed CD40×CEACAM5 Bispecific ...
September 10, 2025
Alligator Bioscience Has Renegotiated the Outstanding Loan From Fenja Capital and Received Subscription Intentions From Members of the Bo...
September 8, 2025
Alligator Bioscience to present at BioStock's "Investing in Life Science" event
September 5, 2025
Alligator Announces Evaluation and Option Agreement Covering RUBY(TM) Antibody Format
September 2, 2025
Exercise Price Determined for the Exercise of Warrants Series TO 13 in Alligator Bioscience AB
August 27, 2025
Alligator Bioscience Provides Highlights from R&D Event 2025
August 20, 2025
Alligator Bioscience to Host Virtual R&D Day on 19 August 2025
August 14, 2025
Alligator Bioscience Announces Upcoming Presentation of REACtiVe-2 Phase 1 Data at ESMO Congress 2025
July 25, 2025
Alligator Bioscience Comments on Henlius Dosing First Patient in the US in Phase 3 Trial of HLX22 in Gastric Cancer
July 14, 2025
Alligator Bioscience AB Reports Financial Results for Q2 2025 and Provides a Business Update
July 10, 2025